Medifast (MED) Tops Q2 EPS by 65c

Medifast (NYSE: MED) reported Q2 EPS of $3.96, $0.65 better than the analyst estimate of $3.31. Revenue for the quarter came in at $394.2 million versus the consensus estimate of $358.45 million.

GUIDANCE:

Medifast sees Q3 2021 EPS of $12.70-$14.17, versus the consensus of $13.80. Medifast sees Q3 2021 revenue of $1.425-1.525 million, versus the consensus of $1.46 million.

For earnings history and earnings-related data on Medifast (MED) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Creatd files Form S-1 and reports Q1 2026 financial results
• Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary